Kidney Cancer

Combination therapy with the novel TKI sitravatinib and the anti–PD-1 immune checkpoint inhibitor nivolumab showed promising efficacy and safety in patients with clear cell renal cell carcinoma and progression after antiangiogenic therapy.

Surgical approach and ischemia time are among key topics.

“The question of who is a candidate for active surveillance is hard to answer because this is a bedside, gut decision," says Primo Nery Lara, Jr, MD.

Gennady Bratslavsky, MD highlighted studies examining (neo)adjuvant immunotherapy in the setting of nephrectomy for locally advanced disease, such as the PROSPER (NCT03055013) and KEYNOTE-564 (NCT03142334) trials.

“One of the reasons I so enjoy this conference is the multidisciplinary nature,” says Peter A. Humphrey, MD, PhD.

“There are, indeed, numerous paths that we are trying to tackle from different angles,” says Gennady Bratslavsky, MD.

In this video, Ryan J. Nelson, DO, and Steven Ogilvy, PA-C, demonstrate the retroperitoneal single-port robotic surgical technique for a kidney tumor.

The approval is based on the pivotal phase 3 KEYNOTE-564 trial.

Naomi B. Haas, MD, discusses efforts to improve care in locally advanced renal cell carcinoma through research in the neoadjuvant setting.

Eric Jonasch, MD, offers his advice for physicians treating patients with renal cell carcinoma.

Sarah Elizabeth Yentz, MD, discusses what sequencing research and novel treatment development is needed to advance the metastatic renal cell carcinoma paradigm.

Ziad Bakouny, MD, MSc, highlights efforts to gain an understanding of the biology and genomic drivers of the rare and aggressive form of kidney cancer.

On this episode of Cleveland Clinic’s Cancer Advances podcast, urologic surgeon Steven Campbell, MD, PhD, discusses the longstanding controversy between partial nephrectomy and radical nephrectomy for patients with localized kidney cancer.

The trial is exploring tivozanib combined with the investigational HIF2α-inhibitor NKT2152 in patients with renal cell carcinoma who have not responded to or have relapsed from prior treatments.

The phase 3 CONTACT-03 trial is specifically accruing patients with inoperable, locally advanced or metastatic renal cell carcinoma with disease progression after receiving an immune checkpoint inhibitor as the immediate prior therapy.

At a median follow-up of 10.4 months (IQR: 5.8-16.4), SAbR extended drug efficacy by more than 6 months in 70% of mRCC patients (14 out of 20; 95% CI: 49.9-90.1).

Eric Jonasch, MD, shares insight on the most pivotal developments in renal cell carcinoma over the past few years.

A retrospective analysis of the phase 3 CheckMate-214 trial showed a treatment-free survival advantage with the immunotherapy combination versus the targeted therapy sunitinib in patients with advanced renal cell carcinoma.

The new drug application is supported by a prior submission for premarket approval of Dovitinib-DRP, a companion diagnostic used to identify patients with RCC most likely to respond to dovitinib.

Adjuvant pembrolizumab was recommended for approval in renal cell carcinoma based on results from the phase 3 KEYNOTE-564 trial.

“The initial phase 1b data of batiraxcept in combination with cabozantinib are impressive and point toward the role of dual AXL and VEGF inhibition in the treatment of clear cell renal cell carcinoma,” said Eric Jonasch, MD.

The approval was based on data from the phase 3 KEYNOTE-564 trial.

Investigators reported that utilizing dosing interruptions or modifications for lenvatinib is an important part of managing toxicities.